Credit Suisse Initiates Coverage On Amphenol with Outperform Rating, Announces Price Target of $93
Credit Suisse analyst Guy Hardwick initiates coverage on Amphenol (NYSE:APH) with a Outperform rating and announces Price Target of $93.
Credit Suisse Initiates Coverage On Zebra Technologies with Outperform Rating, Announces Price Target of $319
Credit Suisse analyst Guy Hardwick initiates coverage on Zebra Technologies (NASDAQ:ZBRA) with a Outperform rating and announces Price Target of $319.
Credit Suisse Initiates Coverage On Vontier with Neutral Rating, Announces Price Target of $21
Credit Suisse analyst Guy Hardwick initiates coverage on Vontier (NYSE:VNT) with a Neutral rating and announces Price Target of $21.
Credit Suisse Initiates Coverage On Cognex with Underperform Rating, Announces Price Target of $41
Credit Suisse analyst Guy Hardwick initiates coverage on Cognex (NASDAQ:CGNX) with a Underperform rating and announces Price Target of $41.
Goldman Sachs Initiates Coverage On Brookfield Asset Mgmt with Buy Rating, Announces Price Target of $40
Goldman Sachs analyst Alexander Blostein initiates coverage on Brookfield Asset Mgmt (NYSE:BAM) with a Buy rating and announces Price Target of $40.
Stifel Initiates Coverage On Hayward Holdings with Buy Rating, Announces Price Target of $11
Stifel analyst W. Andrew Carter initiates coverage on Hayward Holdings (NYSE:HAYW) with a Buy rating and announces Price Target of $11.
Jefferies Initiates Coverage On VectivBio Holding with Buy Rating, Announces Price Target of $18
Jefferies analyst Chris Howerton initiates coverage on VectivBio Holding (NASDAQ:VECT) with a Buy rating and announces Price Target of $18.
JP Morgan Initiates Coverage On Custom Truck One Source with Neutral Rating, Announces Price Target of $7.5
JP Morgan analyst Tami Zakaria initiates coverage on Custom Truck One Source (NYSE:CTOS) with a Neutral rating and announces Price Target of $7.5.
Keybanc Initiates Coverage On Inspire Medical Systems with Overweight Rating, Announces Price Target of $287
Keybanc analyst Matthew Mishan initiates coverage on Inspire Medical Systems (NYSE:INSP) with a Overweight rating and announces Price Target of $287.
Analyst Says Affimed’s ‘Innate Cell Engagers Like No Others,’ Sees Mammoth Upside
H.C. Wainwright initiated coverage on Affimed NV (NASDAQ: AFMD), a clinical-stage biotechnology company focused on developing innate cell engagers (ICEs) for cancer treatment.